AMG 890 for Cardiovascular Disease (CVD)

Phase-Based Progress Estimates
Cardiovascular Disease (CVD)+1 More
AMG 890 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it's safe and effective at reducing levels of Lipoprotein(a) in the blood.

Eligible Conditions
  • Cardiovascular Disease (CVD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

23 Primary · 5 Secondary · Reporting Duration: up to 365 days

Up to 365 days
Change in plasma Lp(a) over time
Changes in PR interval
Changes in QRS interval
Changes in QT interval
Changes in RR interval
Changes in Thrombin time (TT)
Changes in activated partial thromboplastin time (aPTT)
Changes in alanine aminotransferase (ALT) levels (units: U/L)
Changes in albumin levels (units: g/L)
Changes in alkaline phosphatase levels (units: U/L)
Changes in aspartate aminotransferase (AST) levels (units: U/L)
Changes in blood pressure
Changes in direct bilirubin levels (units: μmol/L)
Changes in heart rate
Changes in international normalized ratio (INR)
Changes in platelets
Changes in prothrombin time (PT)
Changes in red blood cells
Changes in respiratory rate
Changes in temperature
Changes in total bilirubin levels (units: μmol/L)
Changes in total protein levels (units: g/L)
Changes in white blood cells
Percent change in plasma Lp(a) over time
up to 365 days
Pharmacokinetics parameter of area under the concentration time curve (AUC)
Pharmacokinetics parameter of maximum observed concentration (Cmax)
Pharmacokinetics parameter of time of maximum observed concentration (tmax)
Subject incidence of treatment-emergent adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

AMG 890
1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

79 Total Participants · 2 Treatment Groups

Primary Treatment: AMG 890 · Has Placebo Group · Phase 1

AMG 890
Experimental Group · 1 Intervention: AMG 890 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 365 days

Who is running the clinical trial?

AmgenLead Sponsor
1,292 Previous Clinical Trials
1,326,870 Total Patients Enrolled
6 Trials studying Cardiovascular Disease (CVD)
6,995 Patients Enrolled for Cardiovascular Disease (CVD)
MDStudy DirectorAmgen
835 Previous Clinical Trials
896,120 Total Patients Enrolled
5 Trials studying Cardiovascular Disease (CVD)
6,940 Patients Enrolled for Cardiovascular Disease (CVD)

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are between the ages of 18 and 70 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.